Similarly, the co-administration of intratumoral ADU-S100 with OX40 agonist and PD-L1 antagonist resulted in the enhanced activation of HER-2-specific CD8+ T cells and clearance of tumor cells in immune-tolerant neu/N mice compared with ADU-S100 monotherapy, suggesting that ICBs can potentiate the anti-tumor effect of CDNs [194]. This evidence concerns the gene TNFRSF4 and neoplasm.